Abrysvo (Pfizer Inc.) is a recombinant antigen vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.
If you have a Hayes login, click here to view the full report on the Knowledge Center.